Hospital days in risperidone-treated patients

被引:7
|
作者
Dickson, RA
Dalby, JT
Addington, D
Williams, R
McDougall, GM
机构
[1] Calgary Gen Hosp, Peter Lougheed Ctr, Reg Clin Dept Psychiat, Carnat Ctr,Specialized Programs Div, Calgary, AB T1Y 6J4, Canada
[2] Univ Calgary, Fac Med, Dept Psychiat, Calgary, AB T2N 1N4, Canada
[3] Univ British Columbia, Vancouver, BC V5Z 1M9, Canada
[4] Univ Victoria, Victoria, BC V8W 2Y2, Canada
[5] Royal Jubilee Hosp, Schizophrenia Program, Victoria, BC, Canada
关键词
schizophrenia; risperidone; outcomes; hospital days;
D O I
10.1177/070674379904400907
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
Objective: To compare inpatient hospital days of a group of "real world" schizophrenia-spectrum patients for 3 years prior to and 3 years after risperidone initiation. Method: This is a retrospective cohort study using a mirror-image design of hospital days in 120 patients over a 6-year period. Hospital admission and discharge information was obtained from chart review and database extraction at 3 outpatient treatment sites. The sample comprised all patients attending these clinics who were prescribed risperidone during the first year of the drug's release. Results: Patients separated into 3 treatment groups. those who were prescribed risperidone for 3 uninterrupted years (N = 35), those who interrupted but resumed risperidone use and were prescribed the drug at 3 years (N = 8), and those who discontinued risperidone during the 3-year follow-up period (N = 77). The group continuing risperidone to 3 years demonstrated a significant decrease in hospital days after risperidone treatment, in contrast to the other 2 groups. The reduction in inpatient days for the total sample was not statistically significant. Conclusion: In this outpatient clinic sample, the 29% of patients who continued on risperidone showed a significant reduction in inpatient hospital days, from an average of 17.2 days per year in the 3 years before risperidone treatment to an average of 2.1 days per year for the 3 years of risperidone treatment.
引用
收藏
页码:909 / 913
页数:5
相关论文
共 50 条
  • [1] Physiogenomic comparison of weight profiles of olanzapine- and risperidone-treated patients
    de Leon, Jose
    Ruaho, Gualberto
    Goethe, John J.
    Caley, Charles
    Woolley, Stephen
    Holford, Theodore R.
    Kocherla, Mohan
    Windemuth, Andreas
    BIOLOGICAL PSYCHIATRY, 2007, 61 (08) : 82S - 82S
  • [2] Physiogenomic comparison of weight profiles of olanzapine- and risperidone-treated patients
    G Ruaño
    J W Goethe
    C Caley
    S Woolley
    T R Holford
    M Kocherla
    A Windemuth
    J de Leon
    Molecular Psychiatry, 2007, 12 : 474 - 482
  • [3] Physiogenomic comparison of weight profiles of olanzapine- and risperidone-treated patients
    Ruano, G.
    Goethe, J. W.
    Caley, C.
    Woolley, S.
    Holford, T. R.
    Kocherla, M.
    Windemuth, A.
    de Leon, J.
    MOLECULAR PSYCHIATRY, 2007, 12 (05) : 474 - 482
  • [4] Prepulse inhibition of the startle response in risperidone-treated patients: comparison with typical antipsychotics
    Kumari, V
    Soni, W
    Sharma, T
    SCHIZOPHRENIA RESEARCH, 2002, 55 (1-2) : 139 - 146
  • [5] REDUCTION OF HOSPITAL DAYS IN CHRONIC-SCHIZOPHRENIC PATIENTS TREATED WITH RISPERIDONE - A RETROSPECTIVE STUDY
    ADDINGTON, DE
    JONES, B
    BLOOM, D
    CHOUINARD, G
    REMINGTON, G
    ALBRIGHT, P
    CLINICAL THERAPEUTICS, 1993, 15 (05) : 917 - 926
  • [6] Serotonin-mediated increase in cytosolic [Ca++] in platelets of risperidone-treated schizophrenia patients
    Ereshefsky, L
    Riesenman, C
    True, JE
    Javors, M
    PSYCHOPHARMACOLOGY BULLETIN, 1996, 32 (01) : 101 - 106
  • [7] CHRNA7 Deletions are Enriched in Risperidone-Treated Children and Adolescents
    Gillentine, Madelyn A.
    White, Janson J.
    Grochowski, Christopher M.
    Lupski, James R.
    Schaaf, Christian P.
    Calarge, Chadi A.
    JOURNAL OF CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY, 2017, 27 (10) : 908 - 915
  • [8] Potential bias in testing for hyperprolactinemia and pituitary tumors in risperidone-treated patients: A claims-based study
    Gianfrancesco F.D.
    Pandina G.
    Mahmoud R.
    Wu J.
    Wang R.H.
    Annals of General Psychiatry, 8 (1)
  • [9] Searching for functional SNPs or rare variants in exonic regions of DRD3 in risperidone-treated patients
    Gasso, Patricia
    Mas, Sergi
    Oliveira, Cristina
    Bioque, Miguel
    Parellada, Eduard
    Bernardo, Miquel
    Trias, Gemma
    Comeche, Joaquim
    Lafuente, Amalia
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2011, 21 (04) : 294 - 299
  • [10] An open-label trial of sildenafil addition in risperidone-treated male schizophrenia patients with erectile dysfunction
    Aviv, A
    Shelef, A
    Weizman, A
    JOURNAL OF CLINICAL PSYCHIATRY, 2004, 65 (01) : 97 - 103